Integra LifeSciences Holdings Corporation (IART)

In the past six months, Integra LifeSciences's stock experienced a new 52-week low. Analyst ratings have varied, with a consensus rating of "Reduce". JPMorgan Chase & Co. raised its price target to $13.00 but maintained an "underweight" rating, while Citigroup decreased its price objective to $11.00 and issued a "sell" rating. Truist Financial reiterated a "hold" rating with a $13.00 price objective. Wall Street Zen upgraded Integra LifeSciences from a "hold" to a "buy" rating in November 2025. In December 2025, Weiss Ratings reissued a "sell (e+)" rating. The company reported its Q3 2025 earnings, exceeding analyst EPS estimates but missing revenue expectations and received FDA clearance for the cardiac use of its CUSA Clarity System in November 2025.

Integra LifeSciences anticipates seasonal demand increases for its products. This seasonality, along with improved Integra Skin production and the resolution of private label supply constraints, is expected to drive recovery in the second half of 2025.

Integra LifeSciences Holdings Corp. is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine, and reconstructive procedures. The company develops and manufactures engineered collagen-based product lines, surgical instruments, implants, and advanced wound care solutions, segmented into Codman Specialty Surgical (CSS) and Tissue Technologies (TT). Its products cater to neurosurgery and neurocritical care, advanced wound care and surgical reconstruction, orthopedic hardware and extremity surgery, surgical instruments and lighting, and ear, nose, and throat (ENT) applications.

Integra LifeSciences markets its solutions globally through direct sales representatives and a network of distributors. The company serves healthcare providers in the United States, Europe, Asia Pacific, and Latin America, with a significant portion of its revenue derived from domestic sales in the United States.

Integra LifeSciences is committed to patient care and aims to be a global leader in medical technologies. The company's brand reputation is tied to its product quality and innovation. Receiving FDA clearance for the cardiac use of its CUSA Clarity System in November 2025 was a positive event. However, the company's operating margin has decreased over the last five years, which could indirectly impact perceptions of efficiency and financial health. The company's CEO has emphasized a commitment to long-term sustainable growth and improved margins.

Institutional investors hold a significant portion of Integra LifeSciences's stock, approximately 84.78% to 85.31%. Major institutional shareholders include BlackRock, Inc., Rubric Capital Management LP, Vanguard Group Inc, iShares Core S&P Small-Cap ETF (IJR), Fuller & Thaler Asset Management, Inc., Morgan Stanley, and Invesco Ltd. Individual investors hold about 3.47% of the shares, and insiders hold approximately 3.33%.